Oncolytics Biotech’s (ONCY) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a research report report published on Monday morning,Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2029 earnings at $0.73 EPS.

Several other research analysts also recently issued reports on ONCY. Royal Bank of Canada dropped their target price on shares of Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating on the stock in a research note on Monday. Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th. Finally, Leede Financial downgraded Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, November 13th. Three equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $4.00.

Oncolytics Biotech Price Performance

ONCY opened at $0.63 on Monday. Oncolytics Biotech has a 1 year low of $0.58 and a 1 year high of $1.53. The stock has a 50-day moving average price of $0.77 and a 200-day moving average price of $0.92. The firm has a market cap of $53.87 million, a PE ratio of -2.33 and a beta of 1.18.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vantage Point Financial LLC purchased a new stake in Oncolytics Biotech during the 4th quarter valued at $27,000. National Bank of Canada FI boosted its stake in shares of Oncolytics Biotech by 199.6% in the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after buying an additional 42,955 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Oncolytics Biotech by 59.6% in the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock worth $61,000 after acquiring an additional 24,997 shares during the period. Virtu Financial LLC purchased a new stake in Oncolytics Biotech during the fourth quarter valued at $90,000. Finally, International Assets Investment Management LLC lifted its holdings in Oncolytics Biotech by 15.0% in the fourth quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock valued at $186,000 after acquiring an additional 26,069 shares during the period. Institutional investors own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.